GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » GENinCode PLC (LSE:GENI) » Definitions » Total Equity

GENinCode (LSE:GENI) Total Equity : £2.81 Mil (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is GENinCode Total Equity?

GENinCode's total equity for the quarter that ended in Jun. 2024 was £2.81 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

GENinCode Total Equity Historical Data

The historical data trend for GENinCode's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GENinCode Total Equity Chart

GENinCode Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Total Equity
-0.44 1.86 13.72 7.90 1.29

GENinCode Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.22 7.90 4.76 1.29 2.81

GENinCode Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

GENinCode's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity=Total Assets(Q: Dec. 2023 )-Total Liabilities(Q: Dec. 2023 )
=4.186-2.897
=1.29

GENinCode's Total Equity for the quarter that ended in Jun. 2024 is calculated as

Total Equity=Total Assets(Q: Jun. 2024 )-Total Liabilities(Q: Jun. 2024 )
=4.661-1.847
=2.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GENinCode Total Equity Related Terms

Thank you for viewing the detailed overview of GENinCode's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

GENinCode Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » GENinCode PLC (LSE:GENI) » Definitions » Total Equity
Comparable Companies
LSE:GDR LSE:VRCI LSE:PRM LSE:ABDX LSE:LLAI LSE:AGL TMO DHR XSWX:LONN IDXX A IQV SHSE:603259 MTD WAT NTRA LH DGX XPAR:BIM ICLR
Traded in Other Exchanges
N/A
Address
Oxford Science Park, John Eccles House, Robert Robertson Avenue, Oxford, GBR, OX4 4GP
Website
https://www.genincode.com
GENinCode PLC is engaged in the genetic risk assessment, prediction, and prevention of cardiovascular diseases including coronary artery diseases such as angina and myocardial infarction (heart attack), stroke, heart failure, hypertension, and other vascular heart diseases. The company's current product portfolio comprises Cardio inCode, LiPID inCode, SuDD inCode, and Thrombo inCode. The company has only one reportable segment the sale of kits and the provision of support services. The Geographic Markets of the group are Chile, France, Italy, Sweden, Mexico, Spain, and the United Kingdom.